Cannabis Goes Head-to-Head With Big Pharma In New Zelira Therapeutics Pain Med Study

Zinger Key Points
  • Zelira says these clinical trials could have major implications for the future of pain management.
  • This is Zelira's first-ever clinical trial of its own products for the treatment of diabetic nerve pain.

Zelira Therapeutics ZLDAFa global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is about to begin a first-ever clinical trial of its own proprietary pain formula for the treatment of diabetic nerve pain against an as-yet-unidentified brand name pain medication, the company announced. 

The trial will evaluate the efficacy, safety and tolerability of Zelira’s patent-protected product.

How Is The Trial Set Up?

The trial is designed as a multi-arm, head-to-head comparison of 60 subjects, with 20 subjects in each arm, powered to show statistical difference. A total of 20 patients in the investigative drug arm have already been enrolled. 

“This product trial exemplifies Zelira’s strategy to continue generating clinical validation for cannabinoid-based medicines,” said Dr. Oludare Odumosu, CEO of Zelira Therapeutics. “We look forward to what we hope will be positive results in this clinical trial and continue to deliver on our ‘multiple shots on goal’ strategy for both our OTC products and our RX prescription cannabinoid products worldwide.”

Partnering with Pennsylvania Global Contract Research Organization (CRO), Affinity Bio Partners to manage the clinical trial, Zelira said they expect results by the end of 2022.

What Else Is Zelira Doing?

Zelira is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain with the goal of providing solutions to patients who are no longer receiving a benefit from their conventional treatments.

The company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. 

Two of the company’s proprietary formulations under the HOPE brand are generating revenues in Australia and Pennsylvania. They have been licensed in Louisiana and Washington D.C., with other US states expected to follow. 

Zelira is also generating revenue in Australia from its proprietary and patented Zenivol, a leading cannabinoid-based medicine for the treatment of chronic insomnia. Zenivol has successfully completed the world’s first Phase 1b clinical trial for chronic insomnia where it was found to be a safe and effective treatment.

Photo courtesy of Zelira

Posted In: Big Pharmaclinical trialDr. Oludare OdumosuPain MedicationBiotechCannabisNewsEntrepreneurshipEurozoneHealth CareSuccess StoriesStartupsSmall BusinessMarketsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.